The Next Front in Abortion Access: Supreme Court Battles Over Mifepristone and Mail-Order Medication

By: Naga Vivekanandan, Esq.

Just when it seemed like the post-Dobbs legal landscape might stabilize, the abortion pill is back at the center of a national legal storm.

On May 14, 2026, the U.S. Supreme Court granted a stay of a Fifth Circuit ruling that would have forced patients to obtain mifepristone in person, ending mail delivery and telehealth prescribing nationwide. For now, the medication remains accessible by mail and at pharmacies. But “for now” is doing a lot of heavy lifting in that sentence. The case will return to the Fifth Circuit for full briefing and argument, and almost certainly will land back at the Supreme Court after that.

Mifepristone has been approved by the FDA (“Food and Drug Administration”) since 2000. For most of its history, the drug carried strict dispensing requirements; patients had to pick it up in person from a certified provider. That changed in 2023, when the FDA, following years of accumulating safety data, eliminated the in-person pickup requirement. Under the updated Risk Evaluation and Mitigation Strategy (“REMS”), mifepristone could be mailed directly to patients and dispensed at retail pharmacies, just like most other prescription drugs.

The 2023 rule change was consequential. Medication abortion, most commonly the combination of mifepristone and misoprostol, now accounts for roughly two-thirds of all abortions in the United States. A quarter of all abortions are now provided via telehealth, a figure that has roughly doubled since Dobbs was decided in 2022. For patients in rural areas or states with bans or those with disabilities that make in-person care difficult or impossible, telehealth access to mifepristone has been, in the words of reproductive rights advocates, a lifeline.

Anti-abortion states wasted no time challenging the 2023 rule. Louisiana filed its own federal lawsuit in October 2025, arguing the FDA failed to adequately support the decision to drop the in-person requirement. The Alliance Defending Freedom filed the case in Louisiana’s Western District on behalf of the state and an individual plaintiff. When the district court declined to immediately reinstate the old dispensing rules, instead pausing the case to let the FDA complete its own ongoing “review” of mifepristone, Louisiana appealed directly to the Fifth Circuit.

On May 1, 2026, a three-judge Fifth Circuit panel sided with Louisiana, reinstating the in-person dispensing requirement immediately and nationwide.

A Week of Legal Chaos

The Fifth Circuit’s May 1 ruling did not just affect Louisiana. Because the court framed it as a remedy under the Administrative Procedure Act, which temporarily voids a nationwide regulatory action, it applied across the country, including in states where abortion is fully legal and protected by state law. Patients in California, New York, and Illinois were suddenly looking at the prospect of driving to a clinic to pick up a prescription they had been receiving in the mail for years.

Within hours of the court’s decision, Danco Laboratories (one of mifepristone’s manufacturers) filed for an emergency stay. The application went to Justice Samuel Alito, who handles emergency requests from the Fifth Circuit. Justice Alito granted a one-week administrative stay while the full Court considered the issue. Then, on May 11, he extended the pause to May 14. Finally, on May 14, the Supreme Court issued a broader stay, allowing mifepristone access by mail and telehealth to continue while the appeal proceeds through the lower courts.

The majority issued no written reasoning, as is typical with emergency orders. But in separate dissents, Justices Alito and Clarence Thomas made their views plain. Justice Alito argued the ruling undermined Dobbs by enabling people to circumvent state abortion bans. Justice Thomas went further, arguing that mailing mifepristone violates the Comstock Act, and that the drug manufacturers, by his logic, “cannot be irreparably harmed by a court order that makes it more difficult for them to commit crimes.”

The Comstock Act: A Zombie Law Returns

That fact that Justice Thomas invoked the Comstock Act in a Supreme Court opinion is worth noting. The Comstock Act is an 1873 anti-obscenity law that bans using U.S. mail to ship any “drug, medicine, or thing” designed to produce an abortion. For most of the twentieth century, the law was treated as a dead letter, superseded by Roe v. Wade and a series of court decisions that rendered it essentially unenforceable. It was never formally repealed.

After Dobbs, however, the Comstock Act took on new life in anti-abortion legal circles. Louisiana’s lawsuit against the FDA argued that the Comstock Act functions as a de facto nationwide ban on mailing abortion medications. The Fifth Circuit’s May 1 ruling did not directly address the Comstock Act question, but other pending cases in Texas and Missouri have gone further, seeking not just to restrict mifepristone’s distribution rules, but also to direct the FDA to withdraw its approval of the drug entirely.

If the Comstock Act theory gains traction, the implications would extend far beyond mifepristone and states with abortion bans. As the ACLU has noted, if anti-abortion courts adopt the theory, it would effectively prohibit mailing the medication and equipment used in abortion care across the entire country.

Justice Thomas’s dissent signals that at least one justice believes this theory has merit. Justice Alito’s dissent suggests a second may be sympathetic.

The FDA’s Position

One of the more unconventional subplots in this story involves the Trump administration’s FDA, which is technically the defendant in Louisiana v. FDA, and has been behaving more like a bystander.

In January 2026, after anti-abortion groups submitted a debunked, self-published report attacking mifepristone’s safety record (a report subsequently criticized by more than 260 expert researchers for severe scientific flaws), HHS Secretary Robert F. Kennedy Jr. asked then-FDA Commissioner Marty Makary to “review” the drug’s data. Rather than defend its 2023 rule change in court, the FDA asked the district court to put the case on hold while the review proceeded.

Danco and GenBioPro, the drug manufacturers who intervened as defendants, were left to fight Louisiana largely on their own. The Trump administration filed no brief with the Supreme Court when the justices took up the emergency stay application. The same week the Supreme Court issued its ruling, Makary resigned under reported White House pressure.

This created what observers have called a “politically motivated” review, which is one designed to avoid any definitive action on mifepristone before the 2026 midterms. A federal court has ordered the FDA to file a status report on its review no later than October 7, 2026.

What Other Lawsuits Are in the Pipeline

Louisiana v. FDA is the most immediately consequential case, but it is not the only one. A full accounting of the mifepristone litigation landscape includes:

• Texas/Florida lawsuit: Filed in December 2025, targeting the FDA’s initial 2000 approval of mifepristone and every subsequent regulatory action easing access. This case could theoretically seek removal of the drug from the market entirely.
• Missouri/Kansas/Idaho lawsuit: Argues the FDA acted improperly when it eased mifepristone restrictions in 2016.
• Bryant v. Stein (North Carolina): A physician argues that the FDA’s dispensing rules preempt state-law restrictions.
• Louisiana state court challenge: Tests whether Louisiana’s classification of mifepristone and misoprostol as controlled substances is constitutional. If upheld, it would subject these medications to controlled-substance storage and prescribing rules, creating yet another access barrier.

Meanwhile, Mississippi passed a new law effective July 1, 2026, making it unlawful to manufacture, distribute, dispense, or prescribe abortion medication, with penalties of up to ten years in prison.

What This Means for Employers and Health Plans

The mifepristone litigation isn’t just a story about individual access to medication. It has very real implications for employers who sponsor health plans, especially self-funded plans with employees nationwide.

Under ERISA, self-insured employer health plans are generally not subject to state insurance mandates. Thus, a self-funded plan can, in principle, cover mifepristone and abortion-related telehealth services even for employees in states that ban those services. ERISA preempts state civil laws that “relate to” employee benefit plans. That’s a meaningful protection, but not an absolute one. ERISA does not preempt “generally applicable criminal” state laws, which is precisely how some ban states have written their restrictions. When criminal liability surfaces, the legal picture for employers gets more complicated.

If the Fifth Circuit’s reinstatement of in-person dispensing requirements is eventually upheld on the merits, plan designs that rely on mail-order pharmacy or telehealth prescribing for reproductive health services will need to be revisited. Even in states where abortion is legal, there would be significant disruption, as patients would have to visit a clinic in person to pick up a medication that could otherwise be delivered to their door.

Texas and Louisiana have attempted to prosecute or fine telehealth providers based in California and New York for prescribing mifepristone to patients in ban states. Those efforts have so far been blocked by shield laws, state laws protecting providers from out-of-state enforcement actions. But employers with multistate workforces whose plans cover out-of-state telehealth providers for reproductive care should be tracking these developments closely.

If the Comstock Act theory gains any judicial traction, even in a lower court, it could create overnight compliance problems for plans that cover mifepristone through mail-order pharmacy. Any plan currently designed that way should have counsel assess its exposure.

The Bigger Picture

What makes the mifepristone cases different from the state abortion ban battles of the past four years is scope. State laws ban abortion within state borders. The theory being advanced in Louisiana v. FDA and in other states is fundamentally different: It would restrict access to a specific medication nationwide, regardless of where a patient lives or what their state allows.

It becomes much larger than a reproductive rights issue. It’s a question about the scope of FDA authority, the limits of state power to challenge federal drug regulation, and whether a 153-year-old anti-obscenity law can effectively override decades of pharmaceutical regulation. The Supreme Court’s May 14 stay offers a temporary reprieve, and access is likely to remain uninterrupted at least through next year as the Louisiana v. FDA case works its way back up through the courts.

For those designing health benefits, advising employers, or simply tracking where abortion access law is headed, this is not a story that is going away.